Buy Wegovy

Buy Wegovy is a prescription medication used for chronic weight management in adults with obesity or overweight with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. It is manufactured by Novo Nordisk and was approved by the U.S. Food and Drug Administration (FDA) in June 2021.

The active ingredient in Wegovy is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide is also used in other medications such as Ozempic, which is indicated for type 2 diabetes management.

Mechanism of Action

Buy Wegovy works by mimicking the GLP-1 hormone, which targets areas of the brain involved in regulating appetite and food intake. By stimulating GLP-1 receptors, it helps to increase feelings of fullness, reduce hunger, and decrease food intake.

Wegovy is indicated for use in adults with a body mass index (BMI) of 30 kg/m² or greater (obesity) or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition. It is intended for use as an adjunct to a reduced-calorie diet and increased physical activity.

Wegovy is administered via subcutaneous injection once weekly. The dosage is gradually increased over 16-20 weeks to 2.4 mg once weekly to minimize gastrointestinal side effects.

The efficacy of Wegovy was evaluated in several clinical trials involving over 4,500 participants. Results showed that individuals taking Wegovy achieved significantly greater weight loss compared to those taking a placebo. In the STEP 1 trial, participants lost an average of 15% of their body weight after 68 weeks.

Common side effects of Wegovy include nausea, diarrhea, vomiting, constipation, and abdominal pain. Serious side effects may include pancreatitis, gallbladder problems, kidney problems, and increased heart rate.

Wegovy is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It is also contraindicated in patients with a history of hypersensitivity to semaglutide or any of the excipients in Wegovy.

Wegovy is available by prescription in the United States and several other countries. Due to high demand, there have been reports of supply shortages since its launch.

Wegovy received FDA approval in June 2021 and has since been approved by regulatory agencies in other regions, including the European Medicines Agency (EMA).

Research and Development

Ongoing research is exploring the potential benefits of semaglutide in other populations and conditions, including adolescents with obesity and individuals with obesity-related conditions like non-alcoholic steatohepatitis (NASH).

References

1. "FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014". U.S. Food and Drug Administration. June 4, 2021.

2. Wilding, J.P.H., et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity". New England Journal of Medicine, 384, 989-1002.

3. "Wegovy (semaglutide) Injection: Information for Patients". Novo Nordisk.